PHAdustry
Creates Industry 4.0 in the era of biomanufacturing
Global Layout
PhaBuilder Global Layout

Global Layout
PhaBuilder Global Layout

Biomanufacturing + Industry 4.0
Learn about and purchase PhaBuilder PHA
The process digital control rate of the synthetic biology production line reaches 80%
The number of fermentation operators is reduced from the usual 4 to 1
Operation and maintenance efficiency is increased by more than 70%
Simultaneously, more than 10,000 sets of fermentation data were captured using biosensors for precision fermentation.
Precision Fermentation Large Model
Modular Replication
Delivering standardized capabilities to the industry
  • Building Big Data

    Biosensors
    10,000+ data modules

  • Building an Industrial AI Large Model

    Modular production
    Scaled replication
    Industry solutions

  • Formulate Precision Production Strategies

    Production strategy optimization
    Precision fermentation

  • Optimizing Supply
  • Reduce Costs
  • Improve Energy Efficiency
  • Sustainability
  • Create a Global Benchmark
Production Line Introduction
Beijing, China
Synthetic Biology Flexible Intelligent Manufacturing Line
The synthetic biology flexible intelligent manufacturing line is located in the northern area of Beijing Sino-German Industrial Park, which is the headquarters of PhaBuilder. It was established in October 2022.
Based on the R&D capabilities of the PHAmily series, the intelligent manufacturing line has diverse product manufacturing capabilities, specifically designed for the production of various types of PHA products that meet a variety of differentiated downstream demands, as well as customized high-value medical implant materials.
  • Multiple Types of PHA

    The production line capable of mass-producing the most types of PHA in the world

  • Transparent Forward and Reverse Fermentation Tank

    The world's first, joint mechanical development with Tsinghua University

  • Digital Operations

    Digital Operations

Production Line Introduction
Shanghai, China
R&D Center
The Shanghai R&D Center is located in Zhangjiang, Shanghai, and is PhaBuilder's innovative layout in March 2024. Relying on Shanghai's superior R&D resources and industrial resources, PhaBuilder connects with global industrial partners to jointly develop PHA-based product solutions.
  • Global Cooperation

    Shanghai’s openness has attracted many foreign-funded enterprises and R&D centers, which has helped introduce international advanced technologies and management experience and improved R&D levels.

  • Complete Industry Chain

    The international level of upstream and downstream industrial chain provides abundant cooperation opportunities and application scenarios for the material research and development center

  • Talent Gathering

    Shanghai gathers the regional headquarters or R&D centers of top pharmaceutical companies from around the world, as well as several well-known universities, which provides both talent and technology support for the materials R&D center and is conducive to carrying out high-level scientific research activities.

Production Line Introduction
Yichang, China
Weiqi Biotechnology
In July 2022, PhaBuilder established Weiqi Biotechnology in a joint venture with Angel Biotech, a world-leading yeast company.
The project is located in Hubei Synthetic Biology Industrial Park, with a total investment of RMB 1.05 billion and a total construction area of over 80,000 square meters.
  • Annual Production of 30,000 Tons

    The world's largest NGIB system biomanufacturing plant

  • Smart Factory

    Combining Industry 4.0 technologies to build a biomanufacturing large model

  • Non-grain Carbon Source

    Capable of utilizing non-grain carbon sources for production and manufacturing

Production Line Introduction
China · West
Weining Biotechnology
In January 2024, PhaBuilder established Weining Biotechnology in a joint venture with listed company Chuanning Biotechnology.
Weining Biotechnology will focus on the medical field, develop medical-grade PHA raw materials and related applications, achieve new breakthroughs in PHA in the field of biomedical materials, and promote the integration of PHA into the global biomedical innovation system.
  • Medical Grade Production Line

    Chuanning Biotechnology’s experience in biomedicine + PhaBuilder's synthetic biology technology

  • BRI Services

    Serve Asian and European customers through the Belt and Road Initiative

  • Integrate PHAdustry

    Global leading technology + experience in industrialization of biomanufacturing + advantage resources in bulk materials